Floatz logo

57 assets in Richter Transformation

Therapeutic assets addressing Richter Transformation, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Obinutuzumab
Richter Transformation
Christine RyanP2BB (71)
Ibrutinib
Richter Transformation
City of Hope Medical CenterP2BB (67)
Venetoclax
Richter Transformation
Northwestern UniversityP2BB (67)
Adriamycin
Richter Transformation
SWOG Cancer Research NetworkP3BB (66)
Cyclophosphamide
Richter Transformation
SWOG Cancer Research NetworkP3BB (66)
Pirtobrutinib
Richter Transformation
SWOG Cancer Research NetworkP3BB (66)
Prednisone
Richter Transformation
SWOG Cancer Research NetworkP3BB (66)
Rituximab
Richter Transformation
SWOG Cancer Research NetworkP3BB (66)
Pembrolizumab
Richter Transformation
Roswell Park Cancer InstituteP2BB (64)
Vincristine Sulfate
Richter Transformation
Yazeed SawalhaP2/3BB (64)
(+)-Vincristine
Richter Transformation
SWOG Cancer Research NetworkP3B (63)
Fludarabine
Richter Transformation
Ohio State University Comprehensive Cancer CenterP2B (62)
Recombinant Human Hyaluronidase
Richter Transformation
SWOG Cancer Research NetworkP3B (62)
Acalabrutinib
Richter Transformation
Mayo ClinicP2B (61)
Atezolizumab
Richter Transformation
Christine RyanP2B (60)
Nivolumab
Richter Transformation
Northwestern UniversityP2B (60)
Oxaliplatin
Richter Transformation
National Heart, Lung, and Blood Institute (NHLBI)P2B (60)
Zilovertamab Vedotin
Richter Transformation
Merck Sharp & Dohme LLCP2B (60)
Bendamustine
Richter Transformation
Mayo ClinicP2B (58)
Etoposide
Richter Transformation
Weill Medical College of Cornell UniversityP2B (58)
Nemtabrutinib
Richter Transformation
Roswell Park Cancer InstituteP2B (58)
Polatuzumab Vedotin
Richter Transformation
Christine RyanP2B (58)
Zanubrutinib
Richter Transformation
City of Hope Medical CenterP2B (58)
Azacitidine
Richter Transformation
National Cancer Institute (NCI)P2/3B (57)
Lenalidomide
Richter Transformation
M.D. Anderson Cancer CenterP1/2B (56)
Brexucabtagene Autoleucel
Richter Transformation
Kite, A Gilead CompanyP2CCC (53)
Durvalumab
Richter Transformation
Mayo ClinicP2CCC (53)
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)
Richter Transformation
Christine RyanP2CCC (53)
Jcar-017 Cd19-Specific Chimeric Antigen Receptor
Richter Transformation
Aseel AlsouqiP2CCC (53)
Prednisolone
Richter Transformation
University of BirminghamP2CCC (53)
Sonrotoclax
Richter Transformation
German CLL Study GroupP2CCC (53)
Tislelizumab
Richter Transformation
German CLL Study GroupP2CCC (53)
Tocilizumab
Richter Transformation
Christine RyanP2CCC (53)
Zamtocabtagene Autoleucel
Richter Transformation
Miltenyi Biomedicine GmbHP2CCC (53)
Epcoritamab
Richter Transformation
National Heart, Lung, and Blood Institute (NHLBI)P1/2CCC (50)
Duvelisib
Richter Transformation
Ruijin HospitalP1/2CCC (49)
Mosunetuzumab
Richter Transformation
GELLC (Grupo Español de Leucemia Linfocítica Crónica)P2CCC (49)
Bgb-16673
Richter Transformation
BeiGeneP1/2CC (47)
Loncastuximab Tesirine
Richter Transformation
City of Hope Medical CenterP2CC (47)
prt2527
Richter Transformation
Prelude TherapeuticsP1CC (47)
CD47/SIRPA-BLOCKING AGENT ALX148
Richter Transformation
M.D. Anderson Cancer CenterP1/2CC (45)
1H-Isoindol-1-one, 2,3-dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)-
Richter Transformation
Nurix Therapeutics, Inc.P1CC (43)
Bgb-21447
Richter Transformation
BeOne MedicinesP1CC (43)
Cart-45 Cells
Richter Transformation
University of PennsylvaniaP1CC (43)
cd19.20.22 car t cells
Richter Transformation
University of Maryland, BaltimoreP1CC (43)
cd45be-hspc
Richter Transformation
University of PennsylvaniaP1CC (43)
lp-118
Richter Transformation
Newave Pharmaceutical IncP1CC (43)
Anti-Cd20/Cd3 Monoclonal Antibody Regn1979
Richter Transformation
City of Hope Medical CenterP1CC (41)
Autologous Anti-Cd19 Car-Expressing T-Lymphocytes Ic19/1563
Richter Transformation
Mayo ClinicP1CC (41)
Autologous Baffr-Targeting Car T Cells
Richter Transformation
Mayo ClinicP1CC (41)
Showing 1 to 50 of 57 assets
PreviousPage 1 of 2Next